Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Issue 6 (June 2015)

• Record Type: Journal Article
• Authors: Boquimpani, Carla; Schaffel, Rony; Biasoli, Irene; Bendit, Israel; Spector, Nelson
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 6(2015:Jun.)
• Page Start: 1787
• Page End: 1792
• Publication Date: 2015-06
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.974047
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>Early molecular response (MR) defined by <italic>BCR–ABL^IS</italic> levels has prognostic impact in chronic myeloid leukemia (CML). MR was evaluated at 3 and 6 months after switching to nilotinib or dasatinib in 115 patients with resistance to imatinib. Three groups were delineated at 3 months (&lt; 1%, 1–10% or &gt; 10% <italic>BCR–ABL^IS</italic> levels) with different outcomes at 3 years regarding major molecular response (MMR, 91%, 47%, 22%, <italic>p</italic> &lt; 0.001), failure-free survival (FFS), progression-free survival (PFS, 96%, 89% and 78%, <italic>p</italic> = 0.05) and overall survival (OS). After 6 months, patients with MR &lt; 1% had higher 3-year MMR (83% vs. 16%, <italic>p</italic> &lt; 0.001), FFS, PFS (94% vs. 84%, <italic>p</italic> = 0.05) and OS. Four patients had 3-month and 6-month MR &gt; 10% and &lt; 1%, respectively (3-year FFS 50%). Thirteen had 3-month and 6-month MR &lt; 10% and ≥ 1%, respectively (3-year FFS 38%). These findings confirm the strong predictive value of 3-month and 6-month <italic>BCR–ABL^IS</italic> levels in imatinib-resistant patients.</p> </abstract>